In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia

Hong Seok Park, Jun Cheon, H. Y. Cho, Y. H. Ko, Jae Hyun Bae, Du Geon Moon, Je-Jong Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

To develop a novel gene therapeutic modality for the effective treatment of benign prostatic hyperplasia (BPH), we investigated the properties of toxic gene therapy utilizing prostate-specific antigen (PSA) promoter driving herpes simplex virus thymidine kinase (HSV-TK) suicide gene to induce highly selective molecular ablation of epithelial cells with minimal systemic toxicity in canine prostate. Replication-defective recombinant adenoviral vectors containing HSV-TK gene under transcriptional control of long PSA promoter (Ad-PSA-HSV-TK) were developed and delivered in an situ manner. Briefly, laparotomies were performed and Ad-PSA-HSV-TK (1 × 109 PFUs) was injected into the left lateral lobe of prostate only on days 1 and 7 with appropriate prodrug acyclovir in adult Beagle dogs. The therapeutic efficacy was evaluated on the 56th experimental day. The striking apoptosis of epithelial cells was identified in the treated left half of canine prostate on TUNEL assay. On immunohistochemical studies, there was markedly decreased number of PSA-secreting epithelial cells compared to control. Also significant atrophy of prostate glands, associated with dense infiltration of lymphocytes and plasma cells, was identified in the treated side. The PSA promoter-based suicide gene therapy induced highly selective and definite ablation of epithelial cells in benign canine prostate. Our novel approach could open opportunity of gene therapeutic modality for the treatment of clinical BPH.

Original languageEnglish
Pages (from-to)1129-1134
Number of pages6
JournalGene Therapy
Volume10
Issue number13
DOIs
Publication statusPublished - 2003 Jul 1

Fingerprint

Prostatic Hyperplasia
Prostate-Specific Antigen
Genetic Therapy
Suicide
Prostate
Simplexvirus
Thymidine Kinase
Epithelial Cells
Canidae
Genes
Therapeutics
Acyclovir
Poisons
In Situ Nick-End Labeling
Prodrugs
Plasma Cells
Laparotomy
Atrophy
Dogs
Lymphocytes

Keywords

  • Prostate-specific antigen
  • Prostatic hyperplasia

ASJC Scopus subject areas

  • Genetics

Cite this

In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia. / Park, Hong Seok; Cheon, Jun; Cho, H. Y.; Ko, Y. H.; Bae, Jae Hyun; Moon, Du Geon; Kim, Je-Jong.

In: Gene Therapy, Vol. 10, No. 13, 01.07.2003, p. 1129-1134.

Research output: Contribution to journalArticle

@article{3057c1af30ca485b8fe193afd0b5455e,
title = "In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia",
abstract = "To develop a novel gene therapeutic modality for the effective treatment of benign prostatic hyperplasia (BPH), we investigated the properties of toxic gene therapy utilizing prostate-specific antigen (PSA) promoter driving herpes simplex virus thymidine kinase (HSV-TK) suicide gene to induce highly selective molecular ablation of epithelial cells with minimal systemic toxicity in canine prostate. Replication-defective recombinant adenoviral vectors containing HSV-TK gene under transcriptional control of long PSA promoter (Ad-PSA-HSV-TK) were developed and delivered in an situ manner. Briefly, laparotomies were performed and Ad-PSA-HSV-TK (1 × 109 PFUs) was injected into the left lateral lobe of prostate only on days 1 and 7 with appropriate prodrug acyclovir in adult Beagle dogs. The therapeutic efficacy was evaluated on the 56th experimental day. The striking apoptosis of epithelial cells was identified in the treated left half of canine prostate on TUNEL assay. On immunohistochemical studies, there was markedly decreased number of PSA-secreting epithelial cells compared to control. Also significant atrophy of prostate glands, associated with dense infiltration of lymphocytes and plasma cells, was identified in the treated side. The PSA promoter-based suicide gene therapy induced highly selective and definite ablation of epithelial cells in benign canine prostate. Our novel approach could open opportunity of gene therapeutic modality for the treatment of clinical BPH.",
keywords = "Prostate-specific antigen, Prostatic hyperplasia",
author = "Park, {Hong Seok} and Jun Cheon and Cho, {H. Y.} and Ko, {Y. H.} and Bae, {Jae Hyun} and Moon, {Du Geon} and Je-Jong Kim",
year = "2003",
month = "7",
day = "1",
doi = "10.1038/sj.gt.3301972",
language = "English",
volume = "10",
pages = "1129--1134",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "13",

}

TY - JOUR

T1 - In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia

AU - Park, Hong Seok

AU - Cheon, Jun

AU - Cho, H. Y.

AU - Ko, Y. H.

AU - Bae, Jae Hyun

AU - Moon, Du Geon

AU - Kim, Je-Jong

PY - 2003/7/1

Y1 - 2003/7/1

N2 - To develop a novel gene therapeutic modality for the effective treatment of benign prostatic hyperplasia (BPH), we investigated the properties of toxic gene therapy utilizing prostate-specific antigen (PSA) promoter driving herpes simplex virus thymidine kinase (HSV-TK) suicide gene to induce highly selective molecular ablation of epithelial cells with minimal systemic toxicity in canine prostate. Replication-defective recombinant adenoviral vectors containing HSV-TK gene under transcriptional control of long PSA promoter (Ad-PSA-HSV-TK) were developed and delivered in an situ manner. Briefly, laparotomies were performed and Ad-PSA-HSV-TK (1 × 109 PFUs) was injected into the left lateral lobe of prostate only on days 1 and 7 with appropriate prodrug acyclovir in adult Beagle dogs. The therapeutic efficacy was evaluated on the 56th experimental day. The striking apoptosis of epithelial cells was identified in the treated left half of canine prostate on TUNEL assay. On immunohistochemical studies, there was markedly decreased number of PSA-secreting epithelial cells compared to control. Also significant atrophy of prostate glands, associated with dense infiltration of lymphocytes and plasma cells, was identified in the treated side. The PSA promoter-based suicide gene therapy induced highly selective and definite ablation of epithelial cells in benign canine prostate. Our novel approach could open opportunity of gene therapeutic modality for the treatment of clinical BPH.

AB - To develop a novel gene therapeutic modality for the effective treatment of benign prostatic hyperplasia (BPH), we investigated the properties of toxic gene therapy utilizing prostate-specific antigen (PSA) promoter driving herpes simplex virus thymidine kinase (HSV-TK) suicide gene to induce highly selective molecular ablation of epithelial cells with minimal systemic toxicity in canine prostate. Replication-defective recombinant adenoviral vectors containing HSV-TK gene under transcriptional control of long PSA promoter (Ad-PSA-HSV-TK) were developed and delivered in an situ manner. Briefly, laparotomies were performed and Ad-PSA-HSV-TK (1 × 109 PFUs) was injected into the left lateral lobe of prostate only on days 1 and 7 with appropriate prodrug acyclovir in adult Beagle dogs. The therapeutic efficacy was evaluated on the 56th experimental day. The striking apoptosis of epithelial cells was identified in the treated left half of canine prostate on TUNEL assay. On immunohistochemical studies, there was markedly decreased number of PSA-secreting epithelial cells compared to control. Also significant atrophy of prostate glands, associated with dense infiltration of lymphocytes and plasma cells, was identified in the treated side. The PSA promoter-based suicide gene therapy induced highly selective and definite ablation of epithelial cells in benign canine prostate. Our novel approach could open opportunity of gene therapeutic modality for the treatment of clinical BPH.

KW - Prostate-specific antigen

KW - Prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=0038601428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038601428&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301972

DO - 10.1038/sj.gt.3301972

M3 - Article

VL - 10

SP - 1129

EP - 1134

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 13

ER -